Skip to main content

Table 8 Regression analysis of deviance (Wald III test)

From: Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial

Variable

p-value

Timepoint

 < 0.01

Age (scaled) (per unit increase)

0.06

Sex

0.42

Treatment

0.02

Post dose pain severity

 < 0.01

No of attacks (scaled)

 < 0.01

Historical MBS

0.34

Post-dose FF photophobia

 < 0.01

Post-dose FF phonophobia

 < 0.01

Post-dose FF nausea

 < 0.01

Treatment-timepoint interaction

0.33

  1. Abbreviations: MBS Most bothersome symptom, FF freedom from